stockportfolio.pro
AtaiBeckley Inc. (ATAI)
Healthcare · Biotechnology · NasdaqGM
AtaiBeckley Inc. revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $233,000 | $314,000 | $308,000 | $4.09M |
| Gross profit | — | — | — | — |
| Net income | $-152.38M | $-40.22M | $-149.27M | $-660.05M |
| Net margin | -65401.3% | -12810.2% | -48464.0% | -16142.0% |
Source: AtaiBeckley Inc. SEC filings (10-K).
Explore 4 years of AtaiBeckley Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ATAI in your portfolio →
AtaiBeckley Inc. financial history by metric
About AtaiBeckley Inc.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. The company was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York.
AtaiBeckley Inc. — frequently asked questions
What is AtaiBeckley Inc.'s revenue?
AtaiBeckley Inc. (ATAI) reported revenue of $4.09M for fiscal year 2025, up 1227.6% from the prior year, according to its SEC filings.
Is AtaiBeckley Inc. profitable?
No — ATAI reported a net loss of $-660.05M in fiscal 2025.
What is ATAI's P/E ratio?
AtaiBeckley Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is AtaiBeckley Inc. growing?
ATAI's revenue grew at roughly 159.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does AtaiBeckley Inc. have?
As of fiscal year 2025, ATAI carried roughly $135.40M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is AtaiBeckley Inc.'s market cap?
AtaiBeckley Inc. (ATAI) has a market capitalization of about $1.38B, based on the latest data in our nightly-refreshed cache.
When does AtaiBeckley Inc.'s fiscal year end?
ATAI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from AtaiBeckley Inc.'s official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.